Heinäkuu 2022: Emergen Researchin tuoreimman tutkimuksen mukaan CAR T-soluhoidon maailmanlaajuiset markkinat saavuttivat 1.29 miljardin Yhdysvaltain dollarin koon vuonna 2021 ja niiden odotetaan rekisteröivän 24.9 prosentin CAGR-liikevaihdon ennustejakson aikana. Kasvavan syövän ilmaantuvuuden kaikkialla maailmassa sekä kasvavan syövän aiheuttaman kuolleisuuden odotetaan olevan ensisijaisia liikevaihdon kasvun tekijöitä maailmanlaajuisilla CAR-T-soluterapiamarkkinoilla ennustejakson aikana. Kliinisten kokeiden toiminnan räjähdysmäinen laajentuminen, fuusioiden ja yritysostojen lisääntyminen sekä listautumisannin houkuttelevuus ovat kaikki tekijöitä, jotka myötävaikuttavat liikevaihdon kasvuun globaaleilla CAR T-soluterapiamarkkinoilla.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CAR T-soluterapia market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CAR T-soluterapia market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Raportin merkittävät lisähavainnot osoittavat sen
Vuonna 2021 segmentti diffuusi suuri B-solu lymfooma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with kimeerisen antigeenireseptorin T-soluterapia, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell non-Hodgkin-lymfoomat who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Tässä raportissa tarkastellaan tarkemmin markkinoilla tällä hetkellä toimivia avainyrityksiä, kuten myös niiden yritysprofiileja, tuoteportfolioita, laajentumisstrategioita ja strategisia liittoutumia. Joitakin esimerkkejä tämäntyyppisistä liittoutumista ovat fuusiot ja yritysostot, yhteistyöt ja yhteisyritykset. Tämän lisäksi se tarjoaa kohokohtia yrityksen saavutuksista ja taloudellisesta tilanteesta sekä näkemyksiä yrityksen markkina-alueesta ja globaalista asemasta.
Yritykset, jotka profiloituvat maailmanlaajuisilla CAR T-Cell Therapy -markkinoilla:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. ja Eli Lilly and Company .
Lue lisää maailmanlaajuisesta CAR T-Cell Therapy -markkinaraportista osoitteessa: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
